IP Library Granted Patent US 10,034,845
Granted Patent B2
US 10,034,845 · App. 14/626,339 · Granted Jul 31, 2018

Autoimmune disorder treatment using RXR agonists

Inventors: Roshantha A. Chandraratna (Laguna Hills, CA); Ethan Dmitrovsky (Hanover, NH); Elizabeth Nowak (West Lebanon, NH); Randolph Noelle (Plainfield, NH)
Assignee: lo Therapeutics, Inc.
A61K31/192A61K9/0073A61K31/201A61K31/216A61K31/343A61K31/353A61K31/47A61K31/4704
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,034,845
App. No.
14/626,339
Granted
Jul 31, 2018
Kind
B2
Abstract

The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Claims (11)

1. A method of treating Parkinson's Disease, the method comprising administering to an individual in need thereof a therapeutically effective amount of a RXR agonist having the structure of formula XII:

wherein R is H, lower alkyl of 1 to 6 carbons, or a pharmaceutically acceptable salt of the compound,

wherein the therapeutically effective amount is about 0.001 mg/kg/day to 0.2 mg/kg/day and wherein the individual does not have cachexia.

2. The method according to claim 1 , wherein the RXR agonist is 3,7-di methyl-6(S),7(S)-methano,7-[1,1,4,4-tetramethyl-1,2,3,4-tetrahydronaphth-7-yl]2(E),4(E) heptadienoic acid, and has the structure of formula XXIX:

3. The method according to claim 1 , wherein the therapeutically effective amount is at most 0.1 mg/kg/day.

4. The method according to claim 1 , wherein the therapeutically effective amount is about 0.01 mg/kg/day to about 0.1 mg/kg/day.

5. The method according to claim 1 , wherein the said treating reduces a symptom associated with Parkinson's disease and the symptom reduced is inflammation, weakness in muscles or the destruction of CNS tissue.

6. The method according to claim 2 , wherein the RXR agonist is a salt or an ester of formula XXIX.

7. The method of according to claim 4 , wherein said administering comprises oral administration.

8. The method of according to claim 3 , wherein said administering comprises nasal administration.

9. The method according to claim 8 , wherein the therapeutically effective amount is at most 0.01 mg/kg/day.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: CHANDRARATNA, ROSHANTHA A.
To: IO THERAPEUTICS, INC.
Reel/Frame 035228/0080 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2015
From: DMITROVSKY, ETHAN; NOWAK, ELIZABETH; NOELLE, RANDOLPH
To: TRUSTEES OF DARTMOUTH COLLEGE
Reel/Frame 035228/0167 →
Continuity (3)
Continuation 13714051 · Dec 13, 2012
Provisional Application 61570182 · Dec 13, 2011
Related Publication 20150196517A1 · Jul 16, 2015